

**Movantik (naloxegol)  
Effective 02/16/18**

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

### Overview

Movantik is a prescription medicine used to treat constipation that is caused by prescription pain medicines called opioids, in adults with long-lasting (chronic) pain that is not caused by active cancer.

### Coverage Guidelines

Authorization may be granted when the following criteria are met:

1. The patient has a diagnosis of opioid-induced constipation **AND**
  2. The patient is actively using opioid analgesics for chronic, noncancer-related pain **AND**
  3. All other causes of constipation have been ruled out (medication-induced constipation, gastrointestinal [GI] motility issues, GI obstruction, etc.) **AND**
  4. The patient is at least 18 years of age **AND**
  5. The patient has either been started and stabilized on the requested medication (excluding the use of samples)
- OR**
5. The patient has failed dietary and lifestyle modifications **AND**
  6. The patient has experienced an allergy or side effect with or has had at least a 1-week trial resulting in treatment failure or inadequate response with at least two (2) different **laxative** agents such as saline, stimulant, bulk, or osmotic laxatives (e.g., milk of magnesia, lactulose, polyethylene glycol [PEG], psyllium, methylcellulose, magnesium citrate, senna, bisacodyl, etc.)

### Limitations

1. Approvals will be granted for 12 months.

### References



1. Movantik (naloxegol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; February 20185.
2. Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. *N Engl J Med* 2014; 370:2387.
3. UpToDate: Common Strategies for Managing Opioid Induced Constipation [cited December 31, 2018]. Available from: [uptodate.com/contents/constipation-in-the-older-adult](http://uptodate.com/contents/constipation-in-the-older-adult)
4. Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. *Pain*. 2013;154(9):1542-1550. [PubMed 23726675]
5. Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. *J Clin Pharmacol*. 2014;54(12):1375-1382.
6. Movantik (naloxegol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; February 20185.
7. Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. *N Engl J Med* 2014; 370:2387.
8. UpToDate: Common Strategies for Managing Opioid Induced Constipation [cited December 31, 2018]. Available from: [uptodate.com/contents/constipation-in-the-older-adult](http://uptodate.com/contents/constipation-in-the-older-adult)
9. Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. *Pain*. 2013;154(9):1542-1550. [PubMed 23726675]
10. Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. *J Clin Pharmacol*. 2014;54(12):1375-1382.

### **Review History**

04/25/16 – Reviewed

07/2016 – Effective

04/24/17 – Reviewed

02/26/18 – Reviewed in P&T Meeting

### **Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.